Home Biosimilar Antibodies Transmembrane Transporters CD markers Loncastuximab (Anti-CD19)
For research use only. Not for use in humans.

Loncastuximab (Anti-CD19)

Synonyms: B4， B-lymphocyte antigen CD19

Loncastuximab (Anti-CD19) is a monoclonal antibody targeting CD19. It shows antitumor activity and has potential application in non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL). MW :144.38 KD.

Loncastuximab (Anti-CD19)

Quality Control

Batch: A316001 Purity: 99% Protein concentration: 6.03mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Loncastuximab (Anti-CD19) is a monoclonal antibody targeting CD19. It shows antitumor activity and has potential application in non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL). MW :144.38 KD.
References

Product Details

CAS No. 1875032-68-0
Isotype Human IgG1
Source CHO
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03620058 ACTIVE_NOT_RECRUITING Chemotherapy Resistant Acute Lymphoblastic Leukemia; Refractory Acute Lymphoblastic Leukemia University of Pennsylvania 2018-09-27 PHASE1
NCT07549698 RECRUITING Warm Autoimmune Hemolytic Anemia (WAIHA); ITP - Immune Thrombocytopenia; Warm Autoimmune Hemolytic Anemia; Immune Thrombocytopenic Purpura CRISPR Therapeutics AG 2026-06 PHASE1; PHASE2
NCT06925542 RECRUITING SLE (Systemic Lupus); Lupus Erythematosus, Systemic; Lupus Nephritis; Systemic Sclerosis; Inflammatory Myopathy, Idiopathic; Myositis; Diffuse Cutaneous Systemic Sclerosis CRISPR Therapeutics 2025-03-10 PHASE1
NCT05991388 RECRUITING Drug: Odronextamab|Drug: Loncastuximab tesirine|Drug: Rituxi B-cell Non Hodgkin Lymphoma University of Birmingham 2024-05-02 PHASE2; PHASE3
NCT06919939 RECRUITING Drug: Epcoritamab|Drug: Loncastuximab Tesirine Large B-cell Lymphoma; Relapse University of Miami 2026-01-07 PHASE2
NCT07162571 NOT_YET_RECRUITING Acute Lymphobkastic Leukemia; B Cell Lymphoma Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology 2026-01-01 PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2025-10-14)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.